tks,
Decent volume today, someone unloading at 47 a couple of million. and the stock barely moved. Be interesting to see how many IPO bought.
Another disposal adds to the buy back pot.
Once the 10m is completed expect another bigger tranche. |
palisz
2023 accounts suggest £4m
2024 half year gained £2.6m
So approx £6.6m plus |
 Info from IPGroup
Dr. Falk Pharma acquires Kynos Therapeutics, adding acute pancreatitis as a therapeutic focus and further strengthening its development portfolio
29 Oct 2024
Freiburg, Germany, 29. October 2024
Today, Dr. Falk Pharma GmbH announces the successful acquisition of Kynos Therapeutics Ltd., a clinical stage biopharmaceutical company focusing on the development of novel treatments for patients suffering from acute and chronic inflammatory diseases. The company was founded as a spin-out of the University of Edinburgh, Scotland, together with lead investor Epidarex Capital, a leading early-stage transatlantic venture fund, along with IP Group, and Scottish Enterprise. Effective immediately, Kynos Therapeutics will be integrated into the Falk Group.
Kynos Therapeutics’ lead investigational asset is KNS366, a highly potent and selective first-in-class inhibitor of the enzyme kynurenine 3-monooxygenase (KMO). In a Phase I clinical trial, KNS366 was shown to be safe and well-tolerated at multiple doses. The compound also led to a dose-dependent inhibition of the enzyme KMO and modulation of its downstream metabolites.
Dr. Falk Pharma is excited about the addition of KNS366 to its R&D pipeline and will further explore the potential of KNS366 in future clinical trials, initially focusing on acute pancreatitis. This new asset will enhance Dr. Falk Pharma´s expansion into rare digestive and metabolic diseases and conditions.
About KNS366
Kynos Therapeutics’ lead investigational asset KNS366 selectively inhibits the enzyme kynurenine 3-monooxygenase (KMO). KMO is a key enzyme in the tryptophan metabolic pathway and has also been shown to play an important role in modulating immune processes. By inhibiting KMO activity, KNS366 interferes with inflammation and other immune system pathologies by lowering levels of its downstream metabolite – 3- hydroxykynurenine (3HK) – high levels of which have been linked to tissue damage and dysregulation of the immune system during inflammation. Inflammatory diseases including acute pancreatitis trigger an exacerbated, systemic pro-inflammatory response, making KMO inhibitors a promising next-generation treatment option for disorders characterized by severe inflammation.
About acute pancreatitis
Acute pancreatitis is a sudden inflammation of the pancreas that can be triggered by a number of factors. In its severe form, this acute inflammation can cascade to a reaction in the entire body over several days to weeks that can result in systemic inflammation, organ failure, and death. Accordingly, acute pancreatitis requires immediate medical intervention to manage patients’ symptoms and prevent worsening of their condition, often necessitating prolonged hospitalization. Currently, acute pancreatitis occurs in about 240,000 people in Europe and 300,000 people in the United States each year, with 1 in 5 acute pancreatitis patients requiring intensive care. To date, there are no proven or approved treatment options to prevent organ failure and death resulting from severe acute pancreatitis, meaning there is an urgent need for effective treatments.
About partnering with Dr. Falk Pharma
Dr. Falk Pharma engages in a variety of collaboration and partnership models to develop and deliver innovative treatment concepts with great potential. These treatments can be based on any type of pharmacological approach, from small molecules to biologics to novel drug delivery technologies. The company is involved in partnership projects across the range of phases and partners, from all stages of pre-clinical/clinical development and marketing as well as with academic researchers, start-ups, and established companies.
Dr. Falk Pharma is an industry leader in innovative pharmaceutical formulations that deliver active substances to specific functional segments of the gastrointestinal tract. Many of their products have attained standard-of-care status. The company enjoys strong, long-standing collaborations with renowned clinical centres and with academic and clinical key opinion leaders in the fields of gastroenterology, hepatology and metabolic diseases.
About Dr. Falk Pharma GmbH
Dr. Falk Pharma GmbH has been developing and marketing innovative medicines to treat a wide range of gastrointestinal disorders like inflammatory bowel disease or eosinophilic esophagitis as well as hepatobiliary disorders such as primary biliary cholangitis for over 60 years. As the international experts in digestive and metabolic medicine, the company brings together physicians, scientists, and patients to devise new and powerful approaches to patient care. Dr. Falk Pharma engages in pre-clinical and clinical stage research that aims to meaningfully improve therapeutic practice as well as patient health and well-being. A family-owned business with a global presence, Dr. Falk Pharma has ten affiliates in Europe and Australia and is continuously growing. The company has its headquarters and R&D facilities in Freiburg, Germany, its pharmaceutical products are manufactured in Europe, mainly at sites in Germany, France, Italy and Switzerland. Dr. Falk Pharma GmbH employs approximately 1250 individuals globally and 323 in Freiburg.
Further information on Dr. Falk Pharma can be found online: |
I don't get a response from the company, so if someone could drop IR an email and ask the sale price would be good to know. As a public company they can't hide the number! |
In March 2022 it was valued at $17.80m so not massive, But IPO has not mentioned any change, despite progress, in the valuation. So must be a premium to this NAV number
Continues to show that NAV is conservative. A definite plus. |
Dr. Falk Pharma acquires Kynos Therapeutics, adding acute pancreatitis as a therapeutic focus and further strengthening its development portfolio
IPO has 18.2% stake.. absolutely nowhere can I find the price paid.
Kynos has recently reported a successful phase 1 test for acute pancreatitis.
It therefore should be a good price, at least NAV or above!
I guess we'll find out eventually. |
Yes, Currently have a bid just below. Trading around a core position. |
palisz, thanks.
Are you still invested here? |
Thank you palisz, bb2. |
Thank you palisz, bb2. |
The broker tends to miss the first 30 minutes, and last 15 unless there is volume.
The only other instruction is to pay no more than a certain number. In the case of IPO they said has to be at least 20% below NAV... so quite a lot higher.
As a VWAP trade obviously they need some volume to trade so if v quiet I have seen them wait till nearly lunchtime to start. |
The formula goes like this.
Excluding opening and closing cross the broker targets the VWAP ( volume weighted average price) IPO just has to say what percentage it wants. At the end of the previous tranche of buy back this was set as high as 20%.
This time it seems to be around 10% but I haven't been checking so much.
The normal range is 5 - 20% depending on liquidity and the CEO's whim!
The CEO can change the % at any time, without notice. With IPO this has happened a number of times. Often it depends if there is further buying power to come. |
Hi p1nk, yes there is a formula, but not sure of the precise content.
It has some limits if the price jumps up. |
Any idea if they use a formula? |
Against my expectations, volume of the buyback is slowing.
Yesterday only 73,983 shares purchased.
At an average of 500,000 shares a week, the current buyback will take around 20 weeks meaning completion around end of February 2025. |
This is ridiculous!
They’ve made great announcements
They’re buying back shares and it Dallas again?!?
D |
SP dropping below the level it was prior to Featurespace sale announcement [£134m]
Almost as if the market doesn't believe the news. |
Sorry that's a general observation from a mate who is a CMO and Biotech VC investor about the delay. They don't have any inside track. Only also said the mechanism in question isn't particularly novel. |
Any chance you can divulge who has informed you? |
No. I don't think that's possible. And I am informed in fact what's happening isn't normal. |
I'm waiting on Istesso, 3 trials up to a year past completion date now without any results announced. Nothing on their website for a year. IPO the main fund provider with board representation but pretending they don't know what's going on. Really?? |
What is happening?
keep dropping after the earning data regardless the share buyback |
CHRY and IPO have similar market caps.
CHRY has a very clear £40m buyback in operation with another £60m promised (and a debt facility signed to start spending that £60m very soon). IPO has reminded us of a previously-offered £10m and a "maybe we'll give you some more later" despite having far more cash in the bank (even before sales proceeds).
I'm happy to go way over-weight on CHRY and wait for IPO. I suspect that they'll spend the £10m - to little avail I'd imagine - before announcing anything more substantial. Lots of time to get back in or to trade the news when it happens... |
Would guess traders buying IPO lower down taking some profit to derisk could be one factor that has held this back when compared with CHRY for example. |
You've missed the point there. 10m buyback before any proceeds from anything else. |
Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
Hot Features
Premium
